Business
Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals
ESCONDIDO, Calif., January 09, 2026--Enthorin Therapeutics, LLC, a biotechnology company focused on circuit-modulating treatments for neurological and neurodevelopmental disorders, announced that its licensing partner for MRM-3379 (formerly ENT-3379), Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), in December, reported the initiation of the BLOOM Phase 2 clinical study evaluating MRM-3379 in Fragile X syndrome (FXS).
About this update from Mirum Pharmaceuticals, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/75399812cadc0c6673b470b547f69fba"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hHWqbyOAffOtk.ZXQPva9g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/75399812cadc0c6673b470b547f69fba","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/gh6LeM2fn8ScOTInLhcxuQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/75399812cadc0c6673b470b547f69fba","width":1024,"height":512}},"lazy":false},{"type":"text","content":"ESCONDIDO, Calif., January 09, 2026--(BUSINESS WIRE)--Enthorin Therapeutics, LLC, a biotechnology company focused on circuit-modulating treatments for neurological and neurodevelopmental disorders, announced that its licensing partner for MRM-3379 (formerly ENT-3379), Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), in December, reported the initiation of the BLOOM Phase 2 clinical study evaluating MRM-3379 in Fragile X syndrome (FXS).","length":434,"tagName":"p"},{"type":"text","content":"MRM-3379 is an orally available, highly brain-penetrant, selective phosphodiesterase-4D (PDE4D) inhibitor designed to enhance cAMP signaling. The compound was discovered by scientists at Dart Neuroscience (DNS), including current members of Enthorin Therapeutics, and advanced through Phase 1 clinical development at DNS. Preclinical data, including results from an FMR1 knockout mouse model of Fragile X syndrome, suggest that MRM-3379 improves cognition and alleviates behavioral deficits across multiple domains.","length":515,"tagName":"p"},{"type":"text","content":"The entry of MRM-3379 into Fragile X patient trials by Mirum Pharmaceuticals is the culmination of over a decade of diligent scientific research and development by the clinicians and scientists at Enthorin and DNS. Enthorin wants to acknowledge all of the dedicated clinical and scientific staff who participated in the discovery and development of MRM-3379.","length":358,"tagName":"p"},{"type":"text","content":"About Enthorin Therapeutics","length":27,"tagName":"p"},{"type":"text","content":"Enthorin Therapeutics is a clinical stage pharmaceutical company foun...